Finance entity
markets is the sole category represented across all 1 tracked stories. Merck & Co. is most often covered alongside Keytruda, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Last mentioned: 2d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Merck & Co. is most often covered alongside Keytruda, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. Their average consequence score of 8 runs above the beat's 6.3 for that window. Merck & Co. appears in 1 tracked Finance story from March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck & Co.. Shared-story counts are live from our verified record — not editorial picks.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck & Co. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
